Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,985 | 629,302 | 143,321 | 12,556 | -1,636 |
| Depreciation Amortization | 52,522 | 63,445 | 53,220 | 23,252 | 22,563 |
| Income taxes - deferred | -19,053 | 74,829 | 29,739 | 44,518 | 10,697 |
| Accounts receivable | -26,061 | 25,463 | -29,544 | -8,358 | -8,525 |
| Other Working Capital | -11,673 | -7,628 | -37,476 | -11,374 | -12,705 |
| Other Operating Activity | 61,836 | -814,747 | 34,799 | 27,976 | 50,339 |
| Operating Cash Flow | $54,586 | $-29,336 | $194,059 | $88,570 | $60,733 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 616,171 | -325,817 | -409,440 | -57,624 | -20,968 |
| PPE Investments | -4,458 | -2,553 | -887 | -2,156 | -1,850 |
| Net Acquisitions | -382,823 | 800,957 | -5,856 | -26,653 | -93,202 |
| Purchase Of Investment | -500 | -1,000 | N/A | N/A | -1,000 |
| Purchase Sale Intangibles | 1,358 | N/A | -10,000 | 7,054 | -17,695 |
| Other Investing Activity | 3,258 | -4,669 | -7,086 | 7,254 | -17,395 |
| Investing Cash Flow | $231,648 | $466,918 | $-423,269 | $-79,179 | $-134,415 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 12,401 | 1,189,559 | N/A | N/A |
| Debt Repayment | -222,209 | -39,724 | -657,255 | N/A | N/A |
| Common Stock Issued | 3,017 | 2,997 | 110,183 | 4,517 | 6,415 |
| Common Stock Repurchased | -77,998 | -453,428 | -152,962 | -1,966 | -3,901 |
| Other Financing Activity | -13,355 | -7,418 | -160,940 | -10,074 | -7,508 |
| Financing Cash Flow | $-310,545 | $-485,172 | $328,585 | $-7,523 | $-4,994 |
| Exchange Rate Effect | N/A | 83 | -215 | N/A | N/A |
| Beginning Cash Position | 72,273 | 119,780 | 20,620 | 18,752 | 97,428 |
| End Cash Position | 47,962 | 72,273 | 119,780 | 20,620 | 18,752 |
| Net Cash Flow | $-24,311 | $-47,507 | $99,160 | $1,868 | $-78,676 |
| Free Cash Flow | |||||
| Operating Cash Flow | 54,586 | -29,336 | 194,059 | 88,570 | 60,733 |
| Capital Expenditure | -4,458 | -2,553 | -887 | -2,156 | -1,850 |
| Free Cash Flow | 50,128 | -31,889 | 193,172 | 86,414 | 58,883 |